Actually, there was a broader variety of people involved. There was a representative of the cardiology community, a representative of the oncology community, and the head of the Edmonton Radiopharmaceutical Centre, who provided really excellent technical advice as to how these products were distributed and what changes could be made to their distribution to improve the situation. Those were the people from the medical community who were involved. Then there were representatives as well from Health Canada.
On February 5th, 2008. See this statement in context.